Guide
“GLP-1 Near Me”: Why the Local Clinic Is Usually the Expensive Option
A local med-spa and a telehealth provider often dispense from the same class of compounding pharmacy, but the local visit adds premises and staff costs to the same vial.
A local med-spa and a telehealth provider often dispense from the same class of compounding pharmacy, but the local visit adds premises and staff costs to the same vial. Captured telehealth pricing starts at $186 flat; local clinic program fees commonly run several hundred a month.
What does the comparison actually show?
| Route | Typical monthly | Clinical model | Reach |
|---|---|---|---|
| Telehealth, captured | $186 flat | Intake reviewed by a licensed US clinician | All 50 states |
| Local clinic / med-spa | Commonly several hundred | In-person visit | One location |
| Brand via LillyDirect | $299–$449 | Prescriber required | All 50 states |
| Local clinic, unpublished fee | Not published | Varies | Ask before booking |
Which pharmacy fills it? A local clinic and a telehealth platform can both be dispensing from a 503A pharmacy in another state entirely. Proximity to the clinic tells you nothing about proximity to the pharmacy, or about that pharmacy's record.
The check is the same either way: name the pharmacy, look it up on the state board, search the FDA warning-letter database for the brand and its parent company.
Where a local clinic genuinely helps: an in-person clinical relationship, physical examination, and someone to see when something is wrong. Those are real and worth paying for if you value them. They are not what a price comparison measures.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does each route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is a local GLP-1 clinic cheaper than telehealth?
Usually not. A local visit adds premises and staff costs to the same class of compounded vial. Captured telehealth pricing starts at $186 flat.
Does a local clinic mean a local pharmacy?
No. A local clinic and a telehealth platform can both dispense from a 503A pharmacy in another state. Proximity to the clinic says nothing about the pharmacy.
What does a local clinic offer that telehealth does not?
An in-person clinical relationship, physical examination and someone to see in person. Those are real and are not what a price comparison measures.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- How to Verify GLP-1 Claims in AI Search ResultsJournal
- How to Get Tirzepatide Online SafelyPillar / Money
- Henry Meds Tirzepatide ReviewProviders
- GLP-1 and Tirzepatide NewsNews
- GLP-1 and Tirzepatide JournalJournal
- GLP-1 Weight Loss and Muscle PreservationJournal
- GLP-1 Tirzepatide Rank ToolTools
Related coverage
GLP-1 Tirzepatide Rank. ““GLP-1 Near Me”: Why the Local Clinic Is Usually the Expensive Option.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/glp1-near-me-vs-telehealth-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.